Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282333 · ClinicalTrials.gov registry record · Phase 1
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01282333: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01282333 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282333, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell lung cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Veliparib may help cisplatin and gemcitabine hydrochloride work better by making tumor cells more sensitive to the drugs.
Interventions
- DRUG cisplatin
- OTHER pharmacological study
- OTHER diagnostic laboratory biomarker analysis
- DRUG gemcitabine hydrochloride
- DRUG veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282333
The ClinicalTrials.gov registry entry for NCT01282333 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT01282333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01282333 about?
NCT01282333 is a clinical study titled "Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer". This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell lung cancer. Veliparib may stop the growth of tumor cells by blocking some...
What is the current status of trial NCT01282333?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2011-01.
What interventions are being tested in trial NCT01282333?
The interventions under investigation include: cisplatin (DRUG), pharmacological study (OTHER), diagnostic laboratory biomarker analysis (OTHER), gemcitabine hydrochloride (DRUG), veliparib (DRUG).
Who is sponsoring clinical trial NCT01282333?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.